Valuation: Assembly Biosciences, Inc.

Market Cap 512M 448M 414M 380M 719M 49.34B 731M 4.94B 1.94B 24.1B 1.92B 1.88B 83.19B P/E 2026 *
-23.9x
P/E 2027 * -9.01x
Enterprise Value 512M 448M 414M 380M 719M 49.34B 731M 4.94B 1.94B 24.1B 1.92B 1.88B 83.19B EV / Sales 2026 *
11.3x
EV / Sales 2027 * 15.9x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day-3.33%
1 week-7.28%
Current month-5.97%
1 month+10.76%
3 months-11.87%
6 months-12.02%
Current year-24.02%
1 week 25.43
Extreme 25.43
27.4
1 month 24.01
Extreme 24.01
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 31/12/2022
Director of Finance/CFO - 04/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 03/06/2026
Director/Board Member 61 13/12/2017
Director/Board Member 68 05/08/2019
Date Insider Type Main position Quantity % Market Cap.
17/06/26 Sell

Chief Financial Officer

-29 0.0002%
04/06/26 Free

Director

8,000 0.0514%
04/06/26 Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-3.33%-7.28%+36.29%+99.38% 512M
-1.07%-1.27%+0.95%+5.66% 49.7B
-2.85%-6.25%+366.61%+572.09% 38.09B
+1.98%+4.82%+13.71%+61.68% 35.29B
+1.78%+0.73%+32.68%-4.80% 35.13B
+0.06%+1.56%+4.41%+27.42% 27.22B
-3.27%-5.67% - - 16.14B
+1.64%+0.45%+70.86%+121.18% 15.36B
+0.29%+1.02%+14.95%+17.80% 13.89B
-1.21%+0.73%+18.02%-30.96% 13.02B
Average -0.60%-1.21%+62.05%+96.60% 24.44B
Weighted average by Cap. -0.28%-0.66%+75.87%+116.49%

Financials

2026 *2027 *
Net sales 45.47M 39.75M 36.76M 33.73M 63.84M 4.38B 64.95M 438M 172M 2.14B 171M 167M 7.39B 32.25M 28.19M 26.07M 23.92M 45.28M 3.11B 46.06M 311M 122M 1.52B 121M 118M 5.24B
Net income -20.46M -17.89M -16.54M -15.18M -28.73M -1.97B -29.23M -197M -77.5M -963M -76.85M -75.16M -3.32B -56.38M -49.28M -45.57M -41.82M -79.15M -5.43B -80.52M -544M -214M -2.65B -212M -207M -9.16B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
16/07/26 US$25.84 -3.33% 309,430
15/07/26 US$26.73 -0.11% 124,814
14/07/26 US$26.76 -0.74% 104,872
13/07/26 US$26.96 -1.61% 112,993
10/07/26 US$27.40 -1.69% 169,991
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
25.84USD
Average target price
50.00USD
Spread / Average Target
+93.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock